Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 11:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 2,006 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Discrete Clear all

Conditions: Parent-Child Relations, Communication
Interventions: Family-based Telehealth Intervention; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 12 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Ovarian Cancer
Interventions: Use of Purposeful app; Behavioral
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Advanced Solid Tumors, Relapsed/Refractory Lymphoma
Interventions: Alisertib, Itraconazole; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 4
States / cities: St Louis, Missouri • Oklahoma City, Oklahoma • Germantown, Tennessee + 1 more

Conditions: Hematologic Malignancy
Interventions: Thymoglobulin, Cyclophosphamide, Fludarabine, Thiotepa, Melphalan, Mesna, Filgrastim, Blinatumomab, CliniMACS; Drug · Device
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Atrial Fibrillation, Left Atrial Appendage Ligation, Pericardium, Epicardial Mapping, Heart Atria, Cardiac Surgical Procedures, Cardiac Catheterization, Pneumopericardium, Left Atrial Appendage Occlusion
Interventions: Pericardial insufflation with carbon dioxide through a transatrial microcatheter; Procedure
Lead sponsor: Henry Ford Health System; Other
Eligibility: 21 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Atopic Dermatitis
Interventions: FMX114, Vehicle; Drug · Other
Lead sponsor: Vyne Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Miami, Florida • Miramar, Florida • Sugarloaf, Pennsylvania

Conditions: Hematologic Malignancy
Interventions: BBI608, Dexamethasone, Bortezomib, Imatinib, Ibrutinib; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 8
States / cities: Denver, Colorado • Indianapolis, Indiana • Germantown, Tennessee + 4 more

Conditions: Diabetes Mellitus Type 2, Pre-diabetes
Interventions: Iowa Produce Prescription Program (I-PPP), Produce Your Path Behavioral Nutrition Intervention (PYP); Other · Behavioral
Lead sponsor: Iowa State University; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Ames, Iowa

Conditions: Rumination, Major Depressive Disorder, Anxiety
Interventions: Transcranial Magnetic Stimulation; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pancreatic Neoplasms
Interventions: Gemcitabine, LAG-3; Drug · Biological
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Rheumatoid Arthritis
Interventions: Leflunomide, Methotrexate, Ocrelizumab, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 836 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 144
States / cities: Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 116 more

Conditions: Neuropathy;Peripheral, Chemotherapy-induced Peripheral Neuropathy, Neuropathy
Interventions: Voxx Human Performance Technology Socks, Placebo Socks; Device
Lead sponsor: Arash Asher, MD; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Los Angeles, California • Torrance, California

Conditions: Type 1 Diabetes Mellitus
Interventions: CGM and Insulin Pump, Closed-Loop Control System; Device
Lead sponsor: Sansum Diabetes Research Institute; Other
Eligibility: 21 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 3
States / cities: Santa Barbara, California • Rochester, Minnesota • Charlottesville, Virginia

Conditions: Cortical Excitability, Psychiatric Disorder
Interventions: L-theanine, Placebo; Drug
Lead sponsor: Butler Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Aging
Interventions: High Flavanol first then Low Flavanol, Low Flavanol first then High Flavanol; Dietary Supplement
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy, Pharmacokinetics of ASP015K and Midazolam
Interventions: ASP015K, Midazolam; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy
Interventions: Capsaicin, Videofluoroscopic swallow study; Drug · Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 100 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Cardiovascular Risk Factor
Interventions: Choline, Placebo; Dietary Supplement
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Blacksburg, Virginia

Conditions: HIV-1
Interventions: D/C/F/TAF FDC, TAF/FTC FDC, INI Based Regimen; Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 34
States / cities: Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 28 more

Conditions: Cancer
Interventions: The Carevive CPS; Other
Lead sponsor: Carevive Systems, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Billings, Montana

Conditions: Human Volunteers
Interventions: BMN 673; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Healthy Volunteers
Interventions: PF614, Naltrexone Hydrochloride, OxyContin; Drug
Lead sponsor: Ensysce Biosciences; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Hyperpigmentation, Dark Spots
Interventions: Cosmetic dark spot corrector serum; Other
Lead sponsor: Revision Skincare; Industry
Eligibility: 25 Years to 65 Years · Female only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Richardson, Texas

Conditions: Scar Tissue, Hypertrophic Scar, Hypertrophic Scar of Upper Arm (Disorder), Hypertrophic Surgical Scar, Dry Needling
Interventions: True dry needling, Sham dry needling; Other
Lead sponsor: Iran University of Medical Sciences; Other
Eligibility: 20 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Family Telehealth Project for Foster Care Youth

Feasibility and Evaluation of a Self-care App to Enhance Purposeful Living

A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma

TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies

Transatrial Pericardial Separation to Enhance Safety of Subxiphoid Pericardial Access for Left Atrial Appendage Ligation

Safety, Pharmacokinetics and Efficacy of FMX114 Versus Vehicle in Adults With Atopic Dermatitis

A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

Iowa Produce Prescription Program

Decoding and Modulating Affective Brain States

Lag-3 and Gemcitabine for Treatment of Advanced Pancreas Cancer

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)

Voxx Human Performance Technology Socks for Chemotherapy-Induced Peripheral Neuropathy

At Home Study of a Zone-Model Predictive Control (MPC) Controller and a Health Monitoring System (HMS) With the Diabetes Assistant (DiAs) System and Run-to-Run Adaptation

Effects of L-theanine on Motor Cortex Excitability in Healthy Subjects: A Paired-Pulse TMS Study

Role of Flavanols In Cardiovascular Function in Healthy Aging

A Study to Assess Drug Interaction of ASP015K and Midazolam

Normal Breathing and Swallowing in Healthy Volunteers

Choline Supplementation and Cardiovascular Health

A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain

Shared Decision Making in Pain Management Planning in Patients With Cancer

Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers

Evaluation of Oral PF614 Relative to OxyContin (PF614-102)

A 16-week Clinical Study Investigating a Dark Spot Corrector Serum in Women With Moderate Discrete Hyperpigmentation

Effectiveness of Dry Needling in Linear Scar Tissue